非ホジキンリンパ腫および慢性リンパ腫治療市場：治療タイプ別、療法別、地域別、2026年～2032年

非ホジキンリンパ腫および慢性リンパ腫治療市場の評価、2026年～2032年

世界の非ホジキンリンパ腫および慢性リンパ腫の罹患率の上昇は、効果的な治療オプションへの需要を大幅に押し上げ、非ホジキンリンパ腫および慢性リンパ腫治療の採用を推進しています。モノクローナル抗体やCAR T細胞療法を含む標的療法の革新は、市場規模を2024年に92億6,000万米ドルを突破し、2032年には約177億9,000万米ドルの評価額に達する原動力となっています。

これに加えて、診断法の進歩により、これらのリンパ腫をより早期かつ正確に発見できるようになり、非ホジキンリンパ腫および慢性リンパ腫治療の採用に拍車がかかっています。がん研究に対する政府資金の増加と有利な償還政策により、市場は2026年から2032年にかけてCAGR 8.5％で成長します。

非ホジキンリンパ腫および慢性リンパ腫治療市場の評価-2026年～2032年

世界の非ホジキンリンパ腫および慢性リンパ腫の罹患率の上昇は、効果的な治療オプションに対する需要を大幅に押し上げ、非ホジキンリンパ腫および慢性リンパ腫治療の採用を促進しています。モノクローナル抗体やCAR T細胞療法を含む標的療法の革新は、市場規模を2024年に92億6,000万米ドルを突破し、2032年には約177億9,000万米ドルの評価額に達する原動力となっています。

これに加えて、診断法の進歩により、これらのリンパ腫をより早期かつ正確に発見できるようになり、非ホジキンリンパ腫および慢性リンパ腫治療の採用に拍車がかかっています。がん研究に対する政府助成金の増加と有利な償還政策により、市場は2026年から2032年にかけてCAGR 8.5％で成長します。

標的療法と免疫療法の進歩は、非ホジキンリンパ腫および慢性リンパ腫治療の採用をどのように増加させるか？

罹患率の上昇は、非ホジキンリンパ腫（NHL）および慢性リンパ性白血病（CLL）治療市場の主要な促進要因です。米国がん協会によると、2024年には米国で8万470人の新規NHL症例が発生すると予測されています。Lancet Haematology誌に掲載された研究で報告されたように、NHLの世界の発症率は1990年から2017年の間に約45%増加しました。このような患者数の増加は、新規治療法の研究開発への投資の増加に拍車をかけています。

標的療法と免疫療法の進歩は治療アプローチに革命をもたらしました。特定のタイプの非ホジキンリンパ腫に対するYescartaやKymriahなどのCAR T細胞療法のFDA承認は、治療抵抗性患者に対する新たな道を開いた。2024年2月、ロシュ社は第III相POLARIX試験の良好な結果を発表し、前治療歴のないびまん性大細胞型B細胞リンパ腫患者において、ポリビーとR-CHPの併用療法が標準治療と比較して無増悪生存期間を有意に改善したことを明らかにしました。

非ホジキンリンパ腫と慢性リンパ性白血病のリスクは年齢とともに増加するため、世界人口の高齢化はもう一つの重要な市場促進要因です。世界保健機関は、2032年までに世界の6人に1人が60歳以上になると予測しています。この人口動態の変化により、リンパ腫治療に対する需要が増加すると予想されます。さらに、ゲノム・プロファイリングの進歩に支えられた個別化医療アプローチの台頭は、よりオーダーメイドの治療戦略を可能にし、転帰を改善し市場成長を促進する可能性があります。

サイバーセキュリティと非ホジキンリンパ腫および慢性リンパ腫治療のコストはその適用を抑制するか？

非ホジキンリンパ腫（NHL）および慢性リンパ性白血病（CLL）治療市場におけるCAR T細胞療法、標的治療、免疫療法のような先進治療は、特に中低所得国において高額であるため、その有効性にもかかわらず多くの患者のアクセスが制限され、これらの革新的治療の普及を妨げる可能性があります。

もう一つの大きな阻害要因は、現在の治療法に伴う重篤な副作用や合併症の可能性です。化学療法や放射線療法は有効ではあるが、免疫抑制、疲労、臓器障害など様々な副作用を引き起こす可能性があります。CAR T細胞療法や幹細胞移植のような先進療法は、サイトカイン放出症候群や移植片対宿主病のような重篤な合併症のリスクを伴う。これらの副作用は、患者の治療適格性や治療計画の遵守を制限し、全体的な治療成績に影響を与える可能性があります。

特に発展途上地域では、高度な診断ツールや治療へのアクセスが限られていることが大きな課題となっています。また、非ホジキンリンパ腫や慢性リンパ性白血病に対する患者や医療従事者の認識や理解が不足しているため、診断の遅れや最適な治療が行われていないです。これらの地域では、不十分なヘルスケアインフラ、専門的な医療従事者の不足、がん治療への不十分な資金が問題をさらに悪化させ、多くの患者がタイムリーで効果的な治療を受けることを妨げています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 非ホジキンリンパ腫および慢性リンパ腫治療市場：治療タイプ別

• 化学療法
• 免疫療法
• 標的療法
• 放射線療法
• 幹細胞移植

第5章 非ホジキンリンパ腫および慢性リンパ腫治療市場：療法別

• ファーストライン療法
• セカンドライン療法
• 維持療法
• 緩和ケア

第6章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第7章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第8章 競合情勢

• 主要企業
• 市場シェア分析

第9章 企業プロファイル

• F. Hoffmann-La Roche Ltd.
• Celgene Corporation
• Johnson & Johnson
• AbbVie Inc.
• Amgen Inc.
• Eli Lilly and Company
• AstraZeneca plc
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Seattle Genetics, Inc.

第10章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第11章 市場展望付録

• 略語リスト
• 出典と参考文献

Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market Valuation - 2026-2032

The rising incidence of NHL and CLL worldwide is significantly boosting the demand for effective treatment options is propelling the adoption of non-hodgkin's lymphoma and chronic lymphoma treatment. Innovations in targeted therapies, including monoclonal antibodies and CAR T-cell therapy is driving the market size surpass USD 9.26 Billion valued in 2024 to reach a valuation of around USD 17.79 Billion by 2032.

In addition to this, advances in diagnostic methods are enabling earlier and more accurate detection of these lymphomas is spurring up the adoption of non-hodgkin's lymphoma and chronic lymphoma treatment. Increased government funding for cancer research and favorable reimbursement policies are enabling the market to grow at a CAGR of 8.5% from 2026 to 2032.

Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market Valuation - 2026-2032

The rising incidence of NHL and CLL worldwide is significantly boosting the demand for effective treatment options is propelling the adoption of non-hodgkin's lymphoma and chronic lymphoma treatment. Innovations in targeted therapies, including monoclonal antibodies and CAR T-cell therapy is driving the market size surpass USD 9.26 Billion valued in 2024 to reach a valuation of around USD 17.79 Billion by 2032.

In addition to this, advances in diagnostic methods are enabling earlier and more accurate detection of these lymphomas is spurring up the adoption of non-hodgkin's lymphoma and chronic lymphoma treatment. Increased government funding for cancer research and favorable reimbursement policies are enabling the market to grow at a CAGR of 8.5% from 2026 to 2032.

How will Advancements in Targeted Therapies And Immunotherapies Increase Adoption of Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment?

Rising incidence rates are a key driver of the non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market. According to the American Cancer Society, an estimated 80,470 new cases of NHL were expected in the US in 2024. The global incidence of NHL increased by approximately 45% between 1990 and 2017, as reported in a study published in The Lancet Haematology. This growing patient population has spurred increased investment in research and development of novel therapies.

Advancements in targeted therapies and immunotherapies have revolutionized treatment approaches. The FDA approval of CAR T-cell therapies, such as Yescarta and Kymriah, for certain types of NHL has opened new avenues for treatment-resistant patients. In February 2024, Roche announced positive results from their phase III POLARIX study, showing that Polivy plus R-CHP significantly improved progression-free survival compared to the standard of care in previously untreated diffuse large B-cell lymphoma patients.

The aging global population is another significant market driver, as NHL and CLL risk increases with age. The World Health Organization projects that by 2032, 1 in 6 people in the world will be aged 60 years or over. This demographic shift is expected to increase the demand for lymphoma treatments. Additionally, the rise of personalized medicine approaches, supported by advancements in genomic profiling, is enabling more tailored treatment strategies, potentially improving outcomes and driving market growth.

Will Cybersecurity and Costs of Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Restrain Its Application?

The high cost of advanced therapies like CAR T-cell therapy, targeted therapies, and immunotherapies in the non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market, particularly in low- and middle-income countries, can limit access for many patients, despite their efficacy, and hinder widespread adoption of these innovative treatments.

Another significant restraint is the potential for severe side effects and complications associated with current treatment modalities. Chemotherapy and radiation therapy, while effective, can cause a range of adverse effects, including immune suppression, fatigue, and organ damage. Advanced therapies like CAR T-cell therapy and stem cell transplants carry risks of serious complications such as cytokine release syndrome and graft-versus-host disease. These side effects can limit patient eligibility and adherence to treatment plans, impacting overall treatment outcomes.

Limited access to advanced diagnostic tools and treatments, particularly in developing regions, poses a major challenge. There is also a lack of awareness and understanding about NHL and CLL among patients and healthcare providers, leading to delayed diagnoses and suboptimal treatment. Inadequate healthcare infrastructure, shortage of specialized medical professionals, and insufficient funding for cancer care in these regions further exacerbate the issue, preventing many patients from receiving timely and effective treatment.

Category-Wise Acumens

Will Rise in Adoption of Stem Cell Transplantation (SCT) Drive Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market?

Stem Cell Transplantation (SCT) is emerging as a leading treatment option for non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). According to the Center for International Blood and Marrow Transplant Research, the number of autologous stem cell transplants for NHL increased by 35% between 2010 and 2020. The National Marrow Donor Program reported that as of 2024, approximately 22,000 allogeneic transplants are performed annually worldwide for various hematologic malignancies, including NHL and CLL. This growth is driven by improved transplant techniques, reduced complications, and expanded donor pools.

Advancements in SCT protocols have significantly improved outcomes. A study published in the New England Journal of Medicine in February 2024 demonstrated that CAR T-cell therapy followed by autologous SCT increased 3-year progression-free survival rates by 40% compared to standard chemotherapy in relapsed/refractory large B-cell lymphoma patients. In March 2024, Novartis announced promising results from their phase II ELARA trial, showing that Kymriah (tisagenlecleucel) followed by SCT achieved a complete response rate of 85% in follicular lymphoma patients.

The expanding use of haploidentical transplants has broadened SCT accessibility. The National Cancer Institute reported a 150% increase in haploidentical transplants for lymphoma between 2015 and 2024. In April 2024, Gamida Cell received FDA approval for Omisirge, a cell therapy product designed to enhance engraftment in patients undergoing allogeneic SCT. This approval is expected to further boost the adoption of SCT in NHL and CLL treatment, potentially increasing market growth by 15-20% over the next five years.

Which Factors Contributing to Palliative Care Segment's Dominance in Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market?

Palliative care is becoming increasingly crucial in non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment, significantly impacting market dynamics. According to the National Hospice and Palliative Care Organization, referrals for palliative care in hematologic malignancies increased by 40% between 2018 and 2024. A study published in the Journal of Clinical Oncology in January 2024 reported that early integration of palliative care in NHL treatment improved quality of life scores by 30% and reduced hospital readmissions by 25%. This growing recognition of palliative care's value has led to increased investment in specialized programs and services.

The expansion of home-based palliative care services has been a key market driver. The Centers for Medicare & Medicaid Services reported a 60% increase in reimbursements for home-based palliative care for NHL and CLL patients from 2020 to 2024. In March 2024, Amedisys, a leading home health care provider, announced a partnership with the Leukemia & Lymphoma Society to launch a nationwide home-based palliative care program specifically tailored for lymphoma patients. This initiative aims to improve access to specialized care and is projected to serve over 10,000 patients in its first year.

Technological advancements in symptom management have further propelled the palliative care market. The FDA's approval of novel pain management devices and medications specifically for cancer-related pain has expanded treatment options. In February 2024, Johnson & Johnson unveiled a new wearable device for continuous pain monitoring in lymphoma patients, which integrates with telehealth platforms for real-time palliative care interventions. Additionally, Pfizer announced positive results from a phase III trial of a new opioid formulation designed to minimize side effects in hematologic cancer patients, potentially improving the quality of life for those receiving palliative care.

Country/Region-wise Acumens

Will Strong Presence of Key Pharmaceutical Companies in North America Mature Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market?

North America dominating the non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market, driven by high incidence rates and advanced healthcare infrastructure. According to the National Cancer Institute, an estimated 80,470 new cases of NHL were diagnosed in the United States in 2024, representing about 4% of all new cancer cases. The American Cancer Society reported that the 5-year relative survival rate for NHL has improved to 73% as of 2024, up from 69% in 2014. This improvement is largely attributed to the region's early adoption of innovative therapies and significant investment in research and development.

The United States dominates the North American market, bolstered by robust reimbursement policies and a strong presence of key pharmaceutical companies. The Centers for Medicare & Medicaid Services reported a 25% increase in spending on NHL and CLL treatments between 2020 and 2024. In February 2024, Gilead Sciences announced positive results from their phase III ZUMA-7 trial, demonstrating that CAR T-cell therapy Yescarta significantly improved event-free survival compared to standard of care in relapsed or refractory large B-cell lymphoma patients. This breakthrough is expected to further solidify North America's market leadership.

Canada is also contributing significantly to the region's dominance. Health Canada reported a 15% increase in approved clinical trials for NHL and CLL treatments from 2022 to 2024. In March 2024, Canadian biotech company BioVaxys Technology Corp. announced a partnership with the Princess Margaret Cancer Centre to develop a novel immunotherapy for follicular lymphoma. Additionally, the Canadian government's recent allocation of $500 million for cancer research over the next five years, announced in April 2024, is expected to further boost innovation in lymphoma treatments, potentially expanding North America's market share by an additional 3-5% by 2026.

Will Rising Advanced Therapies in Asia Pacific Drive the Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market Growth?

The Asia Pacific region is experiencing rapid growth in the non-hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) treatment market, driven by increasing incidence rates and improving healthcare infrastructure. According to the World Health Organization, the incidence of NHL in Southeast Asia increased by 30% between 2015 and 2024. China's National Cancer Center reported a 25% rise in NHL cases from 2018 to 2024, with an estimated 88,090 new cases in 2024. This growing patient population, coupled with rising healthcare expenditure in countries like India and China, is fueling market expansion.

Improved access to advanced therapies is accelerating market growth. Japan's Pharmaceuticals and Medical Devices Agency approved 15 new treatments for NHL and CLL between 2020 and 2024, a 50% increase from the previous five-year period. In February 2024, BeiGene announced positive results from their phase III ALPINE study, showing that Brukinsa (zanubrutinib) demonstrated superior progression-free survival compared to ibrutinib in CLL patients. This development is expected to significantly impact the Asian market, potentially increasing BeiGene's market share by 10-15% over the next two years.

Competitive Landscape

The non-hodgkin's lymphoma and chronic lymphoma treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the non-hodgkin's lymphoma and chronic lymphoma treatment market include:

• Roche Holding AG
• AbbVie, Inc.
• Gilead Sciences, Inc.
• Novartis International AG
• Bristol-Myers Squibb Company
• Amgen, Inc.
• Johnson & Johnson
• AstraZeneca PLC
• Pfizer, Inc.
• Celgene Corporation
• Merck & Co., Inc.
• Eli Lilly and Company
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Seagen, Inc.
• Astellas Pharma, Inc.
• Bayer AG
• Incyte Corporation
• Kite Pharma (a Gilead Company)
• BeiGene, Ltd.

Latest Developments

• In February 2024, BeiGene's Brukinsa (zanubrutinib) received FDA approval for the treatment of chronic lymphocytic leukemia, based on superior efficacy demonstrated in the ALPINE study compared to ibrutinib.
• In May 2024, Gilead Sciences launched a global phase III trial evaluating a novel bispecific antibody, GS-3583, in combination with standard of care for previously untreated diffuse large B-cell lymphoma patients.

Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market, By Category

• Treatment Type:
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Stem Cell Transplantation
• Therapy:
• First-Line Therapy
• Second-line Therapy
• Maintenance Therapy
• Palliative Care
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market, By Treatment Type

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Stem Cell Transplantation

5. Non-Hodgkin's Lymphoma And Chronic Lymphoma Treatment Market, By Therapy

• First-Line Therapy
• Second-Line Therapy
• Maintenance Therapy
• Palliative Care

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• F. Hoffmann-La Roche Ltd.
• Celgene Corporation
• Johnson & Johnson
• AbbVie Inc.
• Amgen Inc.
• Eli Lilly and Company
• AstraZeneca plc
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Seattle Genetics, Inc.

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References